Next generation ALK TKIs (ceritinib and alectinib) came into our sight and approved by the United States (US) Food and Drug Administration (FDA) for treated patients with crizotinib-intolerant, crizotinib-progressive or crizotinib-resistant ALK-positive NSCLC (http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf, www.accessdata.fda.gov/drugsatfda_docs/label/2014/205755lbl.pdf34s000lbl.pdf). This evidence concerns the gene ALK and non-small cell lung carcinoma.